Article
SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED Patients.
Frontiers in immunology - 1 Jan 2021
Ferré Elise M N, Schmitt Monica M, Ochoa Sebastian, Rosen Lindsey B, Shaw Elana R, Burbelo Peter D, Stoddard Jennifer L, Rampertaap Shakuntala, DiMaggio Tom, Bergerson Jenna R E, Rosenzweig Sergio D, Notarangelo Luigi D, Holland Steven M, Lionakis Michail S
Abstract excerpt
Patients with the monogenic immune dysregulatory syndrome autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), which is caused by loss-of-function mutations in the autoimmune regulator (AIRE) gene, uniformly carry neutralizing autoantibodies directed against type-I interferons (IFNs) and many develop autoimmune pneumonitis, both of which place them at high risk for life-threatening COVID-19...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.